Leqembi Vs. Kisunla: An Alzheimer’s Drug Point-by-Point Comparison
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
Parasites take an enormous toll on human and veterinary health. But researchers may have found a way for patients with brain disorders and a…
On September 26th, Cassava Sciences’ founder and former CEO Remi Barbier, as well as former vice president Lindsay Burns agreed to pay the Securities…
While the world tracks the progress of disease-modifying Alzheimer’s anti-amyloids through the drug development and FDA approval pipeline, there are symptomatic treatments making their…
Treatment with a powerful magnet is one of the newest experimental therapies being used to try to turn back the clock on Alzheimer’s disease….
A new study from the UK suggests that the models used to screen for potential future cases of dementia are not reliable predictors of…
On August 22nd, the UK’s drug regulation agency — UK Medicines and Healthcare products Regulatory Agency — approved Eisai and Biogen’s anti-amyloid drug Leqembi…
Scientists in America have developed a nasal spray that can remove proteins in the brain associated with Alzheimer’s disease – at least, in mice….
What will Alzheimer’s treatment look like in five years? At 2024’s Alzheimer’s Association International Conference in Philadelphia, experts provided a sneak peek into the…
Update 17 July, 2024, 3:14 p.m. ET: Cassava Sciences CEO and SVP of neuroscience have resigned from the company following news of federal probes….
Two people diagnosed with Alzheimer’s claim to have conquered the disease through simple lifestyle changes. Dementia and Alzheimer’s have been the leading killers in…
When neurologists first studied the brains of people with Alzheimer’s, more than 100 years ago, they spotted two abnormal clumps of proteins — beta-amyloid…
As the vast majority of Alzheimer’s drugs fail in clinical trials, some researchers and companies are turning to non-invasive neurotechnology as an alternative approach…
Open your medicine cabinet, and you’ll see many examples of the most common type of medication on the market: Small molecule drugs such as…
According to the 2020 Lancet Commission report, the number of people living with dementia worldwide will almost triple in the coming decades, from 57…